KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Deferred Revenue: 2009-2017

Historic Current Deferred Revenue for Biomarin Pharmaceutical (BMRN) over the last 1 years, with Sep 2017 value amounting to $17.4 million.

  • Biomarin Pharmaceutical's Current Deferred Revenue was N/A to $17.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was $17.4 million, marking a year-over-year change of. This contributed to the annual value of $985,000 for FY2016, which is N/A change from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Current Deferred Revenue stood at $17.4 million for Q3 2017, which was up 1,669.54% from $985,000 recorded in Q4 2016.
  • Over the past 5 years, Biomarin Pharmaceutical's Current Deferred Revenue peaked at $17.4 million during Q3 2017, and registered a low of $985,000 during Q4 2016.
  • Moreover, its 2-year median value for Current Deferred Revenue was $9.2 million (2016), whereas its average is $9.2 million.